An enteric-coated tablet of anaprazole sodium and a preparation method thereof
Patent Information
- Application Number
- TW112106544
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-22
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-02-21
AI Technical Summary
Existing enteric-coated tablets of anaprazole sodium suffer from issues such as strong hygroscopicity, poor compressibility, and process defects like astringency and blackening, making them unsuitable for commercial-scale production.
The formulation of enteric-coated tablets comprising anaprazole sodium with specific weight percentages of disintegrants, alkaline diluents, second diluents, adhesives, and lubricants, along with a two-layer coating, is optimized to improve stability, compressibility, and dissolution properties.
The optimized formulation results in tablets with good disintegration and dissolution properties, stable quality, and suitability for commercial production, ensuring long shelf life and effective treatment of gastric acid-related diseases.
Smart Images

Figure TWG2TB001920141_001 
Figure TWG2TB001920141_002 
Figure TWG2TB001920141_003
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medicine, specifically relating to an enteric-coated tablet of anapramazole sodium, its preparation method, and its use in the preparation of drugs for treating gastric acid-related diseases such as peptic ulcers and gastroesophageal reflux disease. Prior Technology
[0002] Digestive system diseases are among the most common and frequently occurring illnesses, with peptic ulcers affecting approximately 10% to 12% of the total population. Gastric acid is the primary cause of peptic ulcers. Initially, treatment primarily involved using antacids (such as sodium bicarbonate and aluminum hydroxide) to neutralize gastric acid and alleviate symptoms. Since the 1970s, the discovery of gastric acid secretion inhibitors such as H2 receptor antagonists and proton pump inhibitors has ushered in a new era of peptic ulcer treatment. These drugs inhibit gastric acid secretion by irreversibly inhibiting H+, K+-ATPase on the secretory microtubules formed by the apical membrane of parietal cells and on tubular vesicles in the cytoplasm. This approach is characterized by rapid onset of action and high ulcer healing rates, significantly reducing the need for surgical intervention.
[0003] First-generation proton pump inhibitors (OPIs) (omeprazole, lansoprazole, and pantoprazole) have good efficacy and tolerability, but due to significant individual variability in efficacy, the influence of administration time and food on acid-suppressing effect, insufficient duration of acid suppression, and slow onset of action, they are not ideal drugs for treating acid-related diseases. Second-generation PPIs (rabeprazole and esomeprazole) have largely overcome the limitations of first-generation PPIs. They have a rapid onset of acid suppression, maintain a high level of acid suppression throughout the day, provide stable acid suppression in a wide range of patient populations, and have no significant drug interactions.
[0004] Patent application CN201180006795.1 discloses Anaprazole Sodium, with the chemical name (R)-2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfinyl]-6,7-dihydro-3H-benzofurano[5,6-d]imidazolium sodium. Studies have shown that Anaprazole Sodium is a novel proton pump inhibitor with advantages such as a longer half-life, moderate acid suppression, high safety, and low risk of drug interactions. It can be used clinically to treat peptic ulcers and gastroesophageal reflux disease, as well as other acid-related diseases.
[0005] Chemical structural formula:
[0006] Meanwhile, patent application CN201180006795.1 also provides an enteric-coated tablet of anapramazole sodium. However, research has found that the tablets prepared by this formulation have problems such as strong hygroscopicity and poor compressibility. In addition, due to the large friction of materials during the production process, there are process defects such as roughness and blackening of particles. Therefore, it is not suitable for commercial scale-up production. In order to meet the requirements of production and transportation, we have conducted research on anapramazole sodium enteric-coated tablets in order to discover a safe, effective, quality-controllable, and commercially viable drug formulation to meet the needs of clinical medication. Summary of the Invention
[0007] The technical solution of this invention is as follows:
[0008] Option 1: An enteric-coated tablet of sodium anapoxetine, wherein, by weight percentage, the tablet core comprises 5%-30% sodium anapoxetine, 1%-30% disintegrant, 10%-30% alkaline diluent, 30%-70% secondary diluent, 1%-20% binder, and 1%-20% lubricant, wherein the weight ratio of sodium anapoxetine and alkaline diluent is selected from 1:1.5-1:2, and the above-mentioned lubricant is magnesium stearate and talc.
[0009] Option 2: As with Option 1, the enteric-coated tablets, by weight percentage, contain 5%-20% of the above-mentioned anaprazole sodium, preferably 5%-15%, and more preferably 5%-10% of the above-mentioned enteric-coated tablets.
[0010] Option 3: Enteric-coated tablets as in Option 1 or Option 2, wherein, by weight percentage, the alkaline diluent accounts for 10%-25% of the weight of the enteric-coated tablets, preferably 10%-20%, and more preferably 15%-20%.
[0011] Option 4: Enteric-coated tablets as described in any of Options 1-3, wherein the alkaline diluent is selected from one or more of calcium hydrogen phosphate, anhydrous sodium carbonate, magnesium oxide, or disodium hydrogen phosphate; preferably, the alkaline diluent is selected from one or more of magnesium oxide and anhydrous sodium carbonate.
[0012] Option 5: Enteric-coated tablets as described in any of Options 1-4, wherein, by weight percentage, the second diluent accounts for 40%-60% of the weight of the enteric-coated tablets, preferably 50%-60%.
[0013] Option 6: Enteric-coated tablets as described in any of Options 1-5, wherein the second diluent is selected from one or more of pregelatinized starch, lactose, mannitol, and microcrystalline cellulose; preferably, the second diluent is selected from one or more of pregelatinized starch and mannitol.
[0014] Option 7: Enteric-coated tablets as described in any of Options 1-6, wherein, by weight percentage, the disintegrant accounts for 1%-25% of the enteric-coated tablets, preferably 5%-15%, and more preferably 10%-15%.
[0015] Option 8: Enteric-coated tablets as described in any of Options 1-7, wherein the disintegrant is selected from one or more of croscarmellose sodium, sodium hydroxymethyl starch or croscarmellose; preferably, the disintegrant is croscarmellose sodium.
[0016] Option 9: Enteric-coated tablets as described in any of Options 1-8, wherein the disintegrant is added to the enteric-coated tablets in two separate additions; the ratio of the two additions of the disintegrant is selected from 5:1 to 1:3, preferably, the ratio of the two additions of the disintegrant is selected from 5:1, 4:1, 3:1, 2:1, 1:1, 1:2 or 1:3, and more preferably, the ratio of the two additions of the disintegrant is selected from 3:1, 2:1, 1:1, 1:2 or 1:3.
[0017] Option 10: Enteric-coated tablets as described in any of Options 1-9, wherein, by weight percentage, the adhesive accounts for 1%-10% of the weight of the enteric-coated tablets, preferably 1%-5%.
[0018] Option 11: Enteric-coated tablets as described in any of Options 1-10, wherein the adhesive is selected from one or more of copovidone VA64, hydroxypropyl cellulose, povidone, or hydroxypropyl methylcellulose; preferably, the adhesive is one or more of povidone and copovidone VA64.
[0019] Option 12: Enteric-coated tablets as described in any of Options 1-11, wherein, by weight percentage, the lubricant accounts for 1%-10% of the weight of the enteric-coated tablets, preferably 1%-6%.
[0020] Option 13: An enteric-coated tablet as described in any of Options 1-12, wherein the magnesium stearate and talc in the aforementioned lubricant are present in the enteric-coated tablet in a weight ratio of 8:1 to 1:8; preferably, the magnesium stearate and talc in the aforementioned lubricant are present in the enteric-coated tablet in a weight ratio of 5:1 to 1:5; more preferably, the weight ratio of the aforementioned magnesium stearate and talc is selected from 1:1, 1:2, 1:3, 1:4, 1:5, 5:1, 4:1, 3:1 or 2:1; more preferably, the weight ratio of the aforementioned magnesium stearate and talc is selected from 1:1, 1:2, 1:3, 1:4 or 1:5.
[0021] Option 14: An enteric-coated tablet as described in any of Options 1-13, wherein the enteric-coated tablet is coated with a film, preferably, the enteric-coated tablet contains two coating layers, namely an isolation coating layer and an enteric coating layer.
[0022] Option 15: Enteric-coated tablets as in Option 14, wherein the isolation coating layer comprises at least one coating premix, and the isolation coating layer accounts for 1% to 10% of the weight of the enteric-coated tablets, preferably 3% to 8%, by weight percentage.
[0023] Option 16: Enteric-coated tablets as in Option 15, wherein the coating premix is a mixture of one or more substances selected from titanium dioxide, polyethylene glycol, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, and hydroxypropyl cellulose.
[0024] Option 17: Enteric-coated tablets as in Option 14, wherein the enteric coating layer comprises at least one coating premix, and by weight percentage, the enteric coating layer accounts for 1%-20% of the enteric-coated tablets, preferably 5%-15%, and more preferably 7%-11%.
[0025] Option 18: Enteric-coated tablets as in Option 17, wherein the above-mentioned coating premix is a mixture of one or more substances selected from titanium dioxide, brilliant blue aluminum lake, triethyl citrate, tartrazine aluminum lake, polyvinyl acetate phthalate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, talc, polyacrylic acid resin, and allura red aluminum lake.
[0026] Option 19: An enteric-coated tablet as described in any one of Options 14-18, wherein the coating layer also comprises at least one coating dispersant, wherein the coating dispersant is selected from 70% or more of ethanol, preferably 80% of ethanol, preferably 85% of ethanol, preferably 90% of ethanol, and preferably 95% of ethanol.
[0027] Solution 20-1: The present invention also provides a method for preparing enteric-coated tablets as described in any one of Solutions 1-19, comprising the following steps: (1) Mix sodium anapramazole, alkaline diluent, second diluent, and first disintegrant to obtain a premix; (2) Prepare an adhesive solution, wherein the adhesive solution uses 90% or more ethanol as a wetting agent, preferably 95% ethanol or anhydrous ethanol; (3) The adhesive solution obtained in step (2) is mixed with the premixed mixture obtained in step (1), and then granulated. (4) Dry the granules obtained in step (3) and perform dry granulation; (5) Mix the particles obtained in step (4) with the second part of the disintegrant and lubricant to obtain the final mixture; (6) Press the final mixture obtained in step (5) to obtain an ingot core; (7) Coating the ingot core obtained in step (6).
[0028] Solution 20-2: The present invention also provides a method for preparing enteric-coated tablets as described in any one of Solutions 1-19, comprising the following steps: (1) Anaprazole sodium, alkaline diluent, second diluent, and first disintegrant are mixed in a granulator to obtain a premix; (2) Prepare the adhesive solution, using 95% ethanol as a wetting agent; (3) Add the adhesive solution obtained in step (2) to the premix in step (1), adjust the granulator to the appropriate parameters, and granulate; (4) Dry the particles from step (3) in a fluidized bed and dry-granulate them in a granulator; (5) The particles obtained in step (4) are mixed with the second part of disintegrant and lubricant in a mixer to obtain the final mixture; (6) Press the final mixture obtained in step (5) on a press to obtain an ingot core; (7) Coating the ingot core obtained in step (6).
[0029] Option 21: The present invention also provides a method for treating peptic ulcers, ulcer bleeding and gastric acid-related diseases with enteric-coated tablets as described in any of Options 1-19, comprising administering a therapeutically effective amount of enteric-coated tablets to a patient in need of such treatment, which may be administered in any known and acceptable manner in the art, the therapeutically effective amount being adjusted according to the patient’s race, sex, age, weight, medical condition, type of disease, severity of disease, route of administration and related health conditions and other factors known to those skilled in the art.
[0030] Option 22: The present invention also provides a composition of enteric-coated tablets as described in any one of Options 1-19 and one or more other therapeutic agents, wherein such other therapeutic agents may be administered simultaneously or sequentially with the enteric-coated tablets for the treatment of peptic ulcers, ulcer bleeding and diseases related to gastric acid.
[0031] Option 23: The composition of Option 22, wherein the other therapeutic agent is an active ingredient that can be used to treat or prevent peptic ulcers, ulcer bleeding and diseases related to gastric acid.
[0032] Option 24: The composition of Option 23, wherein the other therapeutic agents mentioned above may be selected from: 1. Antibacterial agents, such as β-lactam antibiotics, such as amoxicillin, ampicillin, cefotaxime, cefaclor, or cefixime; macrolides, such as erythromycin or clarithromycin; tetracyclines, such as tetracycline or doxycycline; aminoglycosides, such as gentamicin, kanamycin, or amikacin; quinolones, such as norfloxacin, ciprofloxacin, or enoxacin; others, such as metronidazole, nitrofurantoin, or chloramphenicol; or, preparations containing bismuth salts, such as bismuth citrate, bismuth basic salicylate, bismuth basic carbonate, bismuth basic nitrate, or bismuth basic gallate preparations, etc. 2. Acid-dissolving agents, such as aluminum hydroxide, magnesium hydroxide, magnesium carbonate, and magnesium aluminate; 3. Sedatives, such as tranquilizers, including diaminocycloheptatriene, etc.; 4. Antispasmodics, such as bisacodyl and amyl benzoate; 5. Anticholinergic agents, such as oxybenzylcycloimide and phenolurea; 6. Local anesthetics, such as tetracaine and procaine; 7. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, aspirin, and methoxynaphthylpropionic acid; 8. Steroids or nitrite scavengers, such as ascorbic acid and sulfamethoxazole; 9. Other medications for treating gastric ulcers, such as guanethidine, etc.; 10. Prostaglandin drugs, such as 16,16-dimethylprostaglandin E2, etc.; 11. Histamine H2- antagonists, such as cimetidine.
[0033] [Detailed Description of the Invention] In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. However, for a better understanding of this invention, definitions of some terms are provided below. When the definitions and explanations of the terms provided in this invention differ from the meanings commonly understood by those skilled in the art, the definitions and explanations provided in this invention shall prevail.
[0034] The alkaline diluents described in this invention include, but are not limited to, anhydrous sodium carbonate, calcium hydrogen phosphate, magnesium oxide, disodium hydrogen phosphate, and sodium hydroxide.
[0035] The second diluent described in this invention includes, but is not limited to, starch, lactose, microcrystalline cellulose, pregelatinized starch, mannitol, dextrin, sucrose, etc.
[0036] The adhesives described in this invention include, but are not limited to, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, povidone, copovidone, dextrin, maltodextrin, and maltose. In the technical solution of this invention, the povidone is preferably povidone K30.
[0037] The wetting agents described in this invention include, but are not limited to, ethanol of 90% or more. Specific examples include, but are not limited to, 90% ethanol, 95% ethanol, anhydrous ethanol, etc.
[0038] The disintegrants described in this invention include, but are not limited to, croscarmellose sodium, hydroxymethyl cellulose, calcium hydroxymethyl cellulose, low-substituted hydroxypropyl methyl cellulose, croscarmellose, starch, sodium hydroxymethyl starch, and hydroxypropyl starch.
[0039] The lubricants described in this invention include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, talc, micronized silicone, hydrogenated vegetable oil, polyethylene glycol, magnesium lauryl sulfate, etc.
[0040] The coating dispersant described in this invention includes, but is not limited to, 70% or more of ethanol. Specific examples include, but are not limited to, 70% ethanol, 75% ethanol, 80% ethanol, 85% ethanol, 90% ethanol, 95% ethanol, anhydrous ethanol, etc.
[0041] The pharmaceutical formulation of this invention can be packaged in any packaging that does not affect the stability of the pharmaceutical formulation. For example, the inner packaging can be PVC aluminum-plastic blister packaging, double aluminum packaging, PVDC aluminum-plastic blister packaging, etc., and the outer packaging can be a composite film bag.
[0042] The diseases related to gastric acid described in this invention include, but are not limited to, gastritis, gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, etc.
[0043] As used in this article, "therapeutic effective dose" refers to a dose sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from it. Determining such an effective dose is entirely within the capabilities of someone skilled in the art. For example, a therapeutically effective dose will depend on the severity of the disease being treated, the overall state of the patient's immune system, the patient's general characteristics such as age, weight, and sex, the method of administration of the medication, and any other concurrent treatments, etc.
[0044] Any one or more combinations of the above solutions described in this invention are included within the protection scope of this invention.
[0045] The enteric-coated tablets of the present invention have the following advantages: (1) It has good disintegration and dissolution properties, especially its good acid resistance and rapid dissolution in alkaline media; (2) It is stable in nature and can provide a long shelf life; (3) The production process is robust, the cost is controllable, the repeatability is strong, the product quality is stable and controllable, and it can meet the requirements of commercial production. Simple Explanation of the Diagram
[0046] []
[0047] The accompanying drawings, which are included to provide a further understanding of this disclosure, form part of this application. In the drawings, Figure 1 is a dissolution curve diagram for the investigation of different types of disintegrants; Figure 2 is a dissolution curve diagram for the investigation of different types of alkaline diluents. Implementation
[0048] The following detailed description of the present invention, in conjunction with specific embodiments, further illustrates the above-mentioned content. It should be understood that the following embodiments are for illustrative purposes only and are not intended to limit the scope of protection of this disclosure. Unless otherwise specified in the following embodiments, conventional conditions or manufacturer recommendations apply. Drugs or reagents used without a specified manufacturer are all commercially available conventional products.
[0049] The sodium anaprazole used in the following examples was prepared according to the preparation method of Example 14 in the specification of patent application CN201180006795.1.
[0050] [Example] [1] [A study investigating the effect of the type of disintegrant on enteric-coated tablets] [] 1. Preparation process: (1) Weighing: Weigh out the required amounts of sodium anapramazole, alkaline diluent, secondary diluent, disintegrant, and other raw and auxiliary materials according to the dosage, and set aside for later use; (2) Mixing: Weigh the raw and auxiliary materials and place them in a wet granulation machine, then mix them evenly; (3) Preparation of adhesive solution: Weigh the adhesive according to the required amount and prepare the adhesive solution using 95% ethanol as a wetting agent; (4) Granulation and wet granulation: Add the prepared adhesive solution to the raw and auxiliary materials mixed in step (2), adjust the granulator to the appropriate parameters, and granulate; (5) Drying and dry granulation: The obtained wet granules are dried in a fluidized bed granulator and then dry granulated; (6) Additives and final mixing: Add disintegrants and lubricants according to the particle yield to obtain the final mixture; (7) Pressing: Press the final mixture obtained in step (6) on a pressing machine to obtain the ingot core; (8) Coat the ingot core obtained in step (7) with an isolation layer (the isolation layer increases the weight by 3% - 8%); (9) Coat the product obtained in step (8) with an enteric coating (the enteric coating increases the weight by 7% - 11%). 2. Prescription design Table 1. Formulation Design for Disintegrant Screening [Components] [prescription] [1-1] [prescription] [1-2] Prescription value (mg) Proportion% Prescription value (mg) Proportion% Anaprazole sodium 40 10 40 10 Second diluent Mannitol 206 52 206 52 alkaline diluent magnesium oxide 80 20 80 20 Disintegrant Croscinopovidone (XL-10) (added internally) / / 20 5 Cross-linked carboxymethyl cellulose sodium (added internally) 20 5 / / Adhesive Povidone K30 8 2 / / Disintegrant Croscinopovidone (XL-10) (added) / / 20 5 Cross-linked sodium carboxymethyl cellulose (added externally) 20 5 / / lubricant magnesium stearate 4 1 4 1 talcum powder 20 5 20 5 wetting agent 95% ethanol Appropriate amount / Appropriate amount / 3. Results of the investigation Table 2 Formulation process parameters for disintegrant screening Process parameters Prescription 1-1 Prescription 1-2 Soft material properties With moderate moisture content, it has good granulation properties. Moderate moisture content, loose particles wet granular properties Good granularity, no clumping Good granularity, no clumping Dry granule properties The texture is just right, soft yet firm, and crispy. Medium firmness, with a lot of fine powder Tablet hardness / kg 11 ~ 14 10 ~ 13 Disintegration timeout / min 7 4 Table 3. Particle size distribution analysis in disintegrant screening Prescription 1-1 Prescription 1-2 More than 20 mesh 0.8% 0.3% 20-60 mesh 33.6% 5.5% 60-80 mesh 36.4% 20.4% 80-100 mesh 13.7% 23.0% 100 mesh or less 15.6% 50.7% Table 4. Dissolution effect evaluation of disintegrant screening condition 15 min 30 min 45 min 60 min [prescription] [1-1] 0 days 12.1 91.3 92.8 93.3 40℃ for 6 months 9.9 89.2 91.9 91.4 [prescription] [1-2] 0 days 90.7 95.4 94.8 94.4 40℃ for 6 months 85.5 85.6 85.3 84.7 [Experimental Conclusion:] [] The experimental results showed that the dissolution rate of the tablets prepared with croscarmellose sodium as a disintegrant (Formula 1-1) was lower than that of the tablets prepared with croscarmellose polyvinylpyrrolidone (Formula 1-2) at 15 min. After 30 min, the tablets prepared with both disintegrants were basically completely dissolved with no significant difference. However, the dissolution rate of the tablets prepared with croscarmellose polyvinylpyrrolidone decreased significantly and was incompletely dissolved during accelerated dissolution testing. The dissolution curves of each formulation are shown in Figure 1. In addition, the formulations using croscarmellose polyvinylpyrrolidone as a disintegrant exhibited poor granulation properties and particle size distribution.
[0051] [Example] [2] [Types of Lubricants] and [Effect of ratio on enteric-coated tablets] [] 1. Preparation The formulation was prepared according to the prescription and the preparation process of Example 1. 2. Prescription design Table 5. Formula Design for Screening Lubricant Types and Proportions Components Prescription 2-1 Prescription 2-2 Prescription 2-3 Prescription 2-4 Prescription value / mg Proportion / % Prescription value / mg Proportion / % Prescription value / mg Proportion / % Prescription value / mg Proportion / % Anaprazole sodium 10 10 10 10 10 10 10 10 alkaline diluent magnesium oxide 20 20 20 20 20 20 20 20 Second diluent Mannitol 54 55 54 55 51 52 51 52 Disintegrant Cross-linked carboxymethyl cellulose sodium (added internally) 5 5 5 5 5 5 5 5 Adhesive Povidone K30 2 2 2 2 2 2 2 2 Disintegrant Cross-linked sodium carboxymethyl cellulose (added externally) 5 5 5 5 5 5 5 5 lubricant magnesium stearate 1 1 1 1 1 1 1 1 Silicon dioxide / / 2 2 / / / / talcum powder 2 2 / / 4 4 5 5 wetting agent Anhydrous ethanol Appropriate amount / Appropriate amount / Appropriate amount / Appropriate amount / 3. Observation results: Table 6 Results of the screening of lubricant types and proportions [Special Investigation Project] [prescription] [2-1] [prescription] [2-2] [prescription] [2-3] [prescription] [2-4] Raw ingot hardness / kg 4 ~ 6 / 4 ~ 5 4 ~ 5 Disintegration time / min 4 / 4 4 Is it astringent? No roughness, the surface of the ingot is dark with black spots. The pressing of the ingot begins with a rough, jerky motion. No roughness, the surface of the ingot has darkened slightly. No roughness or dulling, the ingot surface is smooth and does not darken. [Experimental Conclusion:] [] The above findings show that when magnesium stearate and silicon dioxide are used as lubricants, jerking occurs at the beginning of ingot pressing; while using magnesium stearate and talc as lubricants effectively avoids jerking. Specifically, when the lubricant is 1% magnesium stearate and 5% talc, the problems of jerking and black spots appearing on the surface of the raw ingot due to particle wear are effectively avoided. Furthermore, the amounts of magnesium stearate and talc are within the known range and have no significant impact on the disintegration time and dissolution rate of the ingot.
[0052] [Example] [3] [Selection of Alkaline Diluents] [Effects on enteric-coated tablets] [Research] [] 1. Preparation The formulation was prepared according to the prescription and the preparation process of Example 1. 2. Prescription design: Table 7 Formulation Design for the Selection of Alkaline Diluents Components Prescription 1-1 Prescription 3-2 Prescription 3-3 Prescription 3-4 Prescription value / mg Proportion / % Prescription value / mg Proportion / % Prescription value / mg Proportion / % Prescription value / mg Proportion / % Anaprazole sodium 40 10 40 10 40 10 40 10 alkaline diluent magnesium oxide 80 20 60 15 40 10 / / Anhydrous sodium carbonate / / / / / / 80 20 Second diluent Mannitol 206 52 226 57 246 62 206 52 Disintegrant Cross-linked carboxymethyl cellulose sodium (added internally) 20 5 20 5 20 5 20 5 Adhesive Povidone K30 8 2 8 2 8 2 8 2 Disintegrant Cross-linked sodium carboxymethyl cellulose (added externally) 20 5 20 5 20 5 20 5 lubricant magnesium stearate 4 1 4 1 4 1 4 1 talcum powder 20 5 20 5 20 5 20 5 wetting agent 95% ethanol Appropriate amount / Appropriate amount / Appropriate amount / Appropriate amount / 3. Experimental Results: Table 8 Results of the investigation on the types and dosages of alkaline diluents Investigation Project Prescription 1-1 Prescription 3-2 Prescription 3-3 Prescription 3-4 Soft material properties Moderate moisture Good granulation properties Moderate moisture Good granulation properties Slightly damp, with relatively large particles. Rice grain-like Moderate moisture Good granulation properties Loose particles wet granular properties Good granulation properties No clumping Good granulation properties Clump-free The particles are relatively large and resemble rice grains. loose clumps Good granulation properties Clump-free Dry granule properties Medium firmness Crispy Medium firmness Crispy Medium firmness Crispy The particles are relatively soft Tablet hardness / kg 11-14 11-14 11-14 10-13 Disintegration timeout / min 7 7 10 7 Related substances 0 days (%) 1.2 1.4 1.2 1.2 60℃ for 10 days (%) 4.3 5.1 4.8 7.9 Table 9 Dissolution results of alkaline diluent screening batch number Dissolution rate / % 15 min 30 min 45 min 60 min Prescription 1-1 12.1 91.3 92.8 93.3 Prescription 3-2 17.9 97.0 97.2 96.5 Prescription 3-3 15.8 75.9 95.4 96.2 Prescription 3-4 4.5 30.0 46.2 54.3 [Experimental Conclusion:] [] The formulation prepared using anhydrous sodium carbonate as an alkaline diluent has softer particles, poorer stability of related substances, and slow and incomplete dissolution, failing to provide alkaline protection. When magnesium oxide is used as an alkaline diluent, the resulting formulation has particles of moderate hardness, better stability of related substances, and faster and more complete dissolution. The dissolution curves for each formulation are shown in Figure 2. Furthermore, when the ratio of sodium anaprazine to magnesium oxide is 1:1.5-1:2, the process proceeds smoothly, the resulting formulation exhibits good stability of related substances, and at 30 min, the dissolution rates of formulations 3-1 and 3-2 are at least 20% higher than that of formulation 3-3.
[0053] [Example] [4] [The Influence of Wetting Agent Selection on Enteric Coated Tablets] [Research] [] 1. Preparation The formulation was prepared according to the prescription and the preparation process of Example 1. 2. Prescription design Table 10 Formulation Design for Wetting Agent Screening Components Prescription 4-1 Prescription 4-2 Proportion% Proportion% Anaprazole sodium (calculated at 40 mg) 10 10 alkaline diluent magnesium oxide 20 20 Second diluent Mannitol 54 54 Disintegrant Cross-linked carboxymethyl cellulose sodium (added internally) 4 4 Adhesive Povidone K30 2 2 Disintegrant Cross-linked sodium carboxymethyl cellulose (added externally) 4 4 lubricant magnesium stearate 1 1 talcum powder 5 5 wetting agent Anhydrous ethanol Appropriate amount / 95% ethanol / Appropriate amount Table 11 Results of the investigation on wetting agent types Investigation Project Prescription 4-1 Prescription 4-2 Types of wetting agents Anhydrous ethanol 95% ethanol wet granular properties Good granularity, moderate moisture content Good granularity, moderate moisture content Dry granule properties Good particle size, with a large number of particles. Good particle size, with a large number of particles. Moisture / % 1.79 1.52 Tablet hardness / kg 11 ~ 15 11 ~ 15 Disintegration timeout / min 6 6 Is there any sticking? none none Table 12 Results of the investigation on wetting agent types - related substances batch number Placement conditions Related substances / % Prescription 4-1 0 days 1.2 60℃ for 10 days 3.8 40℃ / RH 75% 6 months 3.0 Prescription 4-2 0 days 1.3 60℃ for 10 days 2.9 40℃ / RH 75% 6 months 2.5 [Experimental Conclusion] [] The experimental results show that the choice of anhydrous ethanol or 95% ethanol as a wetting agent has no significant impact on particle shape, moisture control, and tablet quality. However, in terms of stability, under the condition of 10 days of storage at 60℃, the increase of related substances in formulation 4-2 is reduced by 30% compared to formulation 4-1. Under the condition of 6 months of storage at 40℃ / RH 75%, the increase of related substances in formulation 4-2 is reduced by 20% compared to formulation 4-1. That is, the choice of 95% ethanol as a wetting agent can effectively reduce the increase of related substances and enhance stability.
Claims
1. An enteric-coated tablet of anapramazole sodium, wherein, by weight percentage, the tablet core comprises 5%-15% anapramazole sodium, 5%-15% disintegrant, 10%-25% alkaline diluent, 40%-60% secondary diluent, 1%-5% binder, and 1%-10% lubricant, wherein the weight ratio of anapramazole sodium to alkaline diluent is selected from 1: The lubricant is magnesium stearate and talc, with the magnesium stearate and talc present in a weight ratio of 8:1 to 1:
8. The disintegrant is croscarmellose sodium, the alkaline diluent is magnesium oxide, the second diluent is mannitol, and the binder is povidone.
2. As in request item 1, enteric-coated tablets, wherein, By weight percentage, the sodium anapramazole accounts for 5% to 10% of the weight of the enteric-coated tablet.
3. Enteric-coated tablets as requested in item 1 or 2, wherein, The alkaline diluent accounts for 10% to 20% of the weight of the enteric-coated tablets by weight.
4. As in request item 3, enteric-coated tablets, wherein, The alkaline diluent accounts for 15% to 20% of the weight of the enteric-coated tablets by weight.
5. Enteric-coated tablets as requested in item 1 or 2, wherein, The second diluent accounts for 50% to 60% of the weight of the enteric-coated tablet by weight.
6. Enteric-coated tablets as requested in item 1 or 2, wherein, The disintegrant is added to the enteric-coated tablet in two separate additions; the ratio of the two additions is selected from 5:1 to 1:
3.
7. As in request item 6, enteric-coated tablets, wherein, The disintegrant accounts for 10% to 15% of the enteric-coated tablets by weight.
8. Enteric-coated tablets as requested in item 1 or 2, wherein, The lubricant accounts for 1% to 6% of the weight of the enteric-coated tablet by weight; the magnesium stearate and talc in the lubricant are present in the enteric-coated tablet in a weight ratio of 5:1 to 1:
5.
9. As requested in item 8, enteric-coated tablets, wherein, The weight ratio of magnesium stearate to talc is selected from 1:1, 1:2, 1:3, 1:4, 1:5, 5:1, 4:1, 3:1 or 2:
1.
10. Enteric-coated tablets as requested in item 1 or 2, wherein, The enteric-coated tablet is coated with a film; the enteric-coated tablet contains two coating layers, namely an isolation coating layer and an enteric coating layer.
11. As in claim 10, enteric-coated tablets, wherein, The isolation coating accounts for 3% to 8% of the weight of the enteric tablet by weight; and 5% to 15% of the weight of the enteric tablet by weight.
12. A method for preparing an enteric-coated tablet as claimed in any one of claims 1 to 11, characterized in that it comprises the following steps: (1) mixing sodium anaprazine, an alkaline diluent, a second diluent, and a first portion of a disintegrant to obtain a premix; (2) preparing an adhesive solution, wherein the adhesive solution uses ethanol of 90% or more as a wetting agent; (3) mixing the adhesive solution obtained in step (2) with the premix in step (1) and granulating; (4) drying the particles obtained in step (3) and dry granulating; (5) mixing the particles obtained in step (4) with a second portion of a disintegrant and a lubricant to obtain a final mixture; (6) pressing the final mixture obtained in step (5) to obtain a core; (7) coating the core obtained in step (6).
13. The preparation method as described in claim 12, wherein, The wetting agent used in step (2) is 95% ethanol or anhydrous ethanol.
Citation Information
Patent Citations
Benzimidazole derivatives and pharmaceutical compositions and uses thereof
CN102712649B
